The role of PARP inhibitor combination therapy in ovarian cancer
Helen Hockings, Rowan Miller
Abstract
The use of PARP inhibitors (PARPi) has transformed the care of advanced high-grade serous/endometrioid ovarian cancer. PARPi are now available to patients in both the first-line and recurrent platinum-sensitive disease settings; therefore, most patients will receive PARPi at some point in their treatment pathway. The majority of this expanding population of patients eventually acquire resistance to PARPi, in addition to those with primary PARPi resistance. We discuss the rationale behind developing combination therapies, to work synergistically with PARPi and overcome mechanisms of resistance to restore drug sensitivity, and clinical evidence of their efficacy to date.
Topics & Concepts
MedicinePARP inhibitorOvarian cancerOncologyDrug resistanceDiseasePopulationInternal medicineCancerPoly ADP ribose polymeraseMicrobiologyEnvironmental healthBiologyChemistryPolymeraseBiochemistryGenePARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentAdvancements in Semiconductor Devices and Circuit Design